



**HAL**  
open science

# Ciproxifan, a Histamine H<sub>3</sub>-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat

Catherine Pillot, Jordi Ortiz, Anne Héron, Sophie Ridray, Jean-Charles Schwartz, Séverine Morisset-Lopez

► **To cite this version:**

Catherine Pillot, Jordi Ortiz, Anne Héron, Sophie Ridray, Jean-Charles Schwartz, et al.. Ciproxifan, a Histamine H<sub>3</sub>-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat. *Journal of Neuroscience*, 2002, 22 (16), pp.7272-7280. hal-01490023

**HAL Id: hal-01490023**

**<https://hal.science/hal-01490023v1>**

Submitted on 14 Mar 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Ciproxifan, a Histamine H<sub>3</sub>-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat

Catherine Pillot,<sup>1</sup> Jordi Ortiz,<sup>1</sup> Anne Héron,<sup>1</sup> Sophie Ridray,<sup>1</sup> Jean-Charles Schwartz,<sup>2</sup> and Jean-Michel Arrang<sup>2</sup>

<sup>1</sup>Laboratoire de Physiologie, Faculté des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France, and <sup>2</sup>Unité de Neurobiologie et Pharmacologie Moléculaire de l'Institut National de la Santé et de la Recherche Médicale, Centre Paul Broca, 75014 Paris, France

By using double *in situ* hybridization performed with proenkephalin and H<sub>3</sub>-receptor riboprobes on the same sections from rat brain, we show that histamine H<sub>3</sub> receptors are expressed within striatopallidal neurons of the indirect movement pathway. The majority (~70%) of striatal enkephalin neurons express H<sub>3</sub>-receptor mRNAs.

This important degree of coexpression of proenkephalin and H<sub>3</sub>-receptor mRNAs prompted us to explore the effect of H<sub>3</sub>-receptor ligands on the regulation of enkephalin mRNA expression in the striatum. Acute administration of ciproxifan, a H<sub>3</sub>-receptor antagonist/inverse agonist, did not modify the expression of the neuropeptide by itself but strongly increased the upregulation of its expression induced by haloperidol. This potentiation (1) was suppressed by the administration of (*R*)- $\alpha$ -methylhistamine, a H<sub>3</sub>-receptor agonist, (2) occurred both in the caudate-putamen and nucleus accumbens, and (3) was also observed with a similar pattern on *c-fos* and neurotensin mRNA expression.

Similarly, whereas it was devoid of any motor effect when used alone, ciproxifan strongly potentiated haloperidol-induced locomotor hypoactivity and catalepsy, two behaviors in which striatal neurons are involved. The strong H<sub>3</sub>-receptor mRNA expression in enkephalin neurons suggests that the synergistic neurochemical and motor effects of ciproxifan and haloperidol result from direct H<sub>3</sub>/D<sub>2</sub>-receptor interactions, leading to an enhanced activation of striatopallidal neurons of the indirect movement pathway. The potentiation of the effects of haloperidol by ciproxifan strengthens the potential interest of H<sub>3</sub>-receptor antagonists/inverse agonists to improve the symptomatic treatment of schizophrenia.

**Key words:** histamine; H<sub>3</sub> receptor; ciproxifan; antagonist/inverse agonist; D<sub>2</sub> receptor; haloperidol; enkephalin; neurotensin; *c-fos*; *in situ* hybridization; catalepsy; locomotor activity

The histamine H<sub>3</sub> receptor (H<sub>3</sub>R), a G<sub>i</sub>/G<sub>o</sub>-protein-coupled receptor, was identified as an autoreceptor controlling histamine neuron activity in the brain (Arrang et al., 1983, 1987). Thereafter, it was also shown to modulate the release of various neurotransmitters (Schlicker et al., 1994; Brown et al., 2001). It was recently cloned in human (Lovenberg et al., 1999), guinea pig (Tardivel-Lacombe et al., 2000), and rat (Lovenberg et al., 2000; Morisset et al., 2000; Drutel et al., 2001). Native H<sub>3</sub>Rs display high constitutive activity, and H<sub>3</sub>R antagonists/inverse agonists such as thioperamide and ciproxifan enhance histamine neuron activity *in vivo* (Ligneau et al., 1998; Morisset et al., 2000), a response primarily used to study the involvement of histaminergic neurons in various processes such as wakefulness and cognition (Onodera et al., 1994; Schwartz and Arrang, 2002).

Functional relationships between histamine and dopamine suggest that histaminergic systems could be involved in the pathophysiology of schizophrenia and/or the action of antipsychotics. In animals treated with methamphetamine (Ito et al., 1996;

Morisset et al., 2002) as well as in patients with schizophrenia (Prell et al., 1995), hyperactivity of dopaminergic transmission is accompanied with an enhanced activity of histaminergic neurons. Typical neuroleptics decrease histamine neuron activity, whereas atypical antipsychotics stimulate histamine neurons, an effect that may underlie their pro-cognitive properties (Morisset et al., 1999). Thioperamide and ciproxifan attenuate the locomotor activation induced by dopaminergic agonists (Clapham and Kilpatrick, 1994; Morisset et al., 2002).

High densities of H<sub>3</sub>Rs were found in the striatum where lesions indicated that most H<sub>3</sub>Rs were present on projection neurons (Barbin et al., 1980; Cumming et al., 1991; Pollard et al., 1993; Ryu et al., 1994a,b, 1995; Anichtchik et al., 2000). In agreement, high densities of H<sub>3</sub>R mRNAs were found in the striatum from rat (Lovenberg et al., 1999; Morisset et al., 2001; Drutel et al., 2001; Pillot et al., 2002), guinea pig (Tardivel-Lacombe et al., 2000), and human (Anichtchik et al., 2001).

These observations suggested the presence of H<sub>3</sub>Rs on medium spiny neurons, which represent >90% of striatal neurons (Gerfen, 1992; Parent and Harati, 1995). In agreement, various approaches indicated that H<sub>3</sub>Rs are present on striatonigral neurons of the direct movement pathway. Striatal quinolinic acid lesions decreased, and 6-OHDA lesions increased, the number of H<sub>3</sub>Rs in the striatum and substantia nigra, respectively (Ryu et al., 1994a, 1996). Moreover, activation of H<sub>3</sub>Rs inhibited D<sub>1</sub>-receptor

Received March 20, 2002; revised May 22, 2002; accepted May 23, 2002.

Jordi Ortiz was a recipient of a fellowship from the Biomedicine and Health Programme of the European Commission.

Correspondence should be addressed to Dr. Jean-Michel Arrang, Unité de Neurobiologie et Pharmacologie Moléculaire de l'Institut National de la Santé et de la Recherche Médicale, Centre Paul Broca, 2 ter rue d'Alésia, 75014 Paris, France. E-mail: arrang@broca.inserm.fr.

Copyright © 2002 Society for Neuroscience 0270-6474/02/227272-09\$15.00/0

dependent GABA release in rat substantia nigra and striatum (Garcia et al., 1997; Arias-Montano et al., 2001).

In the present work, we have explored the presence and role of H<sub>3</sub>Rs on GABAergic striatopallidal neurons of the indirect movement pathway, known to contain enkephalin. To this purpose we have (1) analyzed the expression of H<sub>3</sub>R mRNAs in striatal enkephalin neurons by double *in situ* hybridization, (2) evaluated the effect of H<sub>3</sub>R ligands on enkephalin and neurotensin expression in the striatum, and (3) assessed the effect of H<sub>3</sub>R ligands on catalepsy and spontaneous locomotor activity.

## MATERIALS AND METHODS

**Tissue preparation.** All animal experiments performed in the present study conformed to the National Institutes of Health guidelines (décret number 2001–464, May 29, 2001, from the French Ministry of Agriculture). When required, drugs dissolved in saline solution (0.9% NaCl w/v) were administered intraperitoneally. After treatment, male Wistar rats (Iffa-Credo, L'Arbresle, France) were killed by decapitation, their brains were removed rapidly, immediately frozen (–40°C) by immersion in monochlorodifluoromethane, and stored at –70°C. Brain sections (10 μm) were prepared on a cryostat, thaw-mounted onto Superfrost slides, and immediately fixed for 40 min at 4°C in 4% paraformaldehyde made up in 0.1 M PBS, pH 7.4, and 0.1% diethylpyrocarbonate water. Sections were rinsed three times (5 min each) in 0.1 M PBS, pH 7.4, dehydrated through graded ethanol, and dried under a stream of cold air. All the sections were stored at –70°C until use.

**In situ hybridization histochemistry.** Sections were incubated at 37°C for 10 min with proteinase K (1 μg/ml), acetylated for 10 min (in 0.1 M triethanolamine, pH 8, and 0.25% acetic anhydride) at room temperature, and dehydrated in graded ethanol up to 100%. Hybridization was performed overnight at 55°C in the presence of 4 × 10<sup>6</sup> dpm of <sup>33</sup>P-radiolabeled cRNA probes in hybridization buffer (50% formamide, 10% dextran sulfate, 2× SSC, 1× Denhardt's solution, 50 mM Tris-HCl buffer, 0.1% NaPPi, 0.1 mg/ml yeast tRNA, 0.1 mg/ml salmon sperm DNA, and 1 mM EDTA). Subsequently, the sections were rinsed with 2× SSC for 5 min and incubated for 40 min at 37°C with RNase A (200 μg/ml). The sections were then extensively washed in SSC, dehydrated in graded ethanol, dried, and exposed for 8–10 d (H<sub>3</sub>R, proneurotensin, c-fos) to a β<sub>max</sub> Hyperfilm (Amersham, UK). To avoid overexposure of the film caused by the inherently high striatal expression of proenkephalin (PE) mRNAs, sections hybridized with the proenkephalin cRNA probe were exposed only for 8–10 hr.

For the hybridization probes, a partial coding sequence of the rat H<sub>3</sub>R was amplified from striatum cDNAs using primers 1 and 2 based on the sequence of the third transmembrane domain and the third intracellular loop of the human H<sub>3</sub>R, respectively (Lovenberg et al., 1999) (primer 1: 5'-AGTCGATCCAGCTACGACCGCTTCCGTGTC-3' and primer 2: 5'-AGTCAAGCTTGGAGCCCCTCTTGAGTGAGC-3'). The amplified fragment was sequenced and corresponded to nucleotides 636 to 1243 of the rat H<sub>3</sub>R sequence. It was previously shown to hybridize to the various H<sub>3</sub>R mRNA isoforms expressed in the brain or peripheral tissues (Héron et al., 2001; Morisset et al., 2001). The probes for proenkephalin, proneurotensin, and c-fos were also obtained by PCR and corresponded to nucleotides 335–641, nucleotides 169–510, and nucleotides 583–790, respectively. After subcloning of the PCR products into pGEM-4Z (Promega, Charbonnières, France), <sup>33</sup>P-labeled antisense RNA probes were prepared by *in vitro* transcription using a Riboprobe kit (Promega).

For the study of the coexpression of H<sub>3</sub>R mRNAs and proenkephalin mRNAs, sections were covered overnight with 50 μl of the hybridization buffer containing the <sup>33</sup>P-labeled cRNA probe for the H<sub>3</sub>R and a digoxigenin-labeled cRNA probe for proenkephalin. After incubation overnight, the sections were rinsed in SSC and treated with RNase A as described above. The detection of the digoxigenin-labeled probe was performed as described (Bordet et al., 2000). Briefly, the sections were incubated overnight at 4°C with a phosphatase-conjugated antidigoxigenin antibody (Boehringer Mannheim, Mannheim, Germany). After washing, each slide was covered with 500 μl of a chromogen solution, containing nitroblue tetrazolium chloride, 5-bromo-4-chloro-3-indolyl phosphate, and levamisole, to visualize the conjugated antibody. After completion of the reaction at room temperature and in the dark, the slides were washed and rinsed in distilled water. For the detection of the <sup>33</sup>P-labeled riboprobe, the slides were dipped in Ilford K-5 liquid pho-

tographic emulsion for 2 weeks. Dipped sections were then observed with a photomicroscope (Axiophot Zeiss, Carl Zeiss, Germany).

**Spontaneous locomotor activity.** After saline or drug administration, rats were immediately introduced into an actimeter (Imétronic, Pessac, France), consisting in individuals boxes placed in a quiet room. Spontaneous locomotor activity of the animals was evaluated for 60 min by numbering infrared crossed beams.

**Assessment of catalepsy.** Catalepsy was assessed in an all-or-none manner 2 hr after intraperitoneal administration of the drugs. Each rat was placed gently so that both front limbs rested on top of an horizontal rod placed at a height of 10 cm above the floor. An animal was considered to be in catalepsy if it remained with its hind legs on the floor and its front limbs on the rod for >5 sec.

**Data analysis.** For *in situ* hybridization, mRNA signals generated in the caudate–putamen and nucleus accumbens were quantified on two to three sections per animal using a camera and an image analyzer with Starwise/Autorad 210 program (Imstar, Paris, France). Results were means ± SEM of values from 4–10 rats and were expressed as percentages of mRNA levels in control (saline) rats. Statistical evaluation of the results was performed using one-way ANOVA followed by Student–Newman–Keuls test.

For spontaneous locomotor activity, cumulative results were analyzed using one-way ANOVA followed by Student–Newman–Keuls test. When repeated measures were performed at each 10 min interval, between-group differences were analyzed with the Statistica software using two-way ANOVA followed by least significance difference (LSD) *post hoc* tests.

**Radiochemicals and drugs.** Ciproxifan and (*R*)-α-methylhistamine were from Bioprojet (Paris, France). Haloperidol (HAL) was from Janssen Pharmaceutica (Beerse, Belgium).

## RESULTS


### Localization of H<sub>3</sub> receptor and proenkephalin gene transcripts in the striatum

Autoradiograms from frontal sections generated with selective antisense riboprobes revealed a high expression of H<sub>3</sub>R and PE mRNAs both in the caudate–putamen and nucleus accumbens (Fig. 1*A,B*).

The cellular location of both transcripts was analyzed in the caudate–putamen using a <sup>33</sup>P-labeled H<sub>3</sub>R riboprobe and a digoxigenin-labeled PE riboprobe. The vast majority of striatal neurons expressed H<sub>3</sub>R mRNAs, whereas PE mRNA expression was restricted to a smaller population of neurons, in which it occurred at an apparently variable level (Fig. 1*C*). Among PE mRNA-expressing neurons, a limited number did not express H<sub>3</sub>R mRNAs (Fig. 1*D*), but the majority (~70%) coexpressed H<sub>3</sub>R and PE mRNAs (Fig. 1*F*).

### Effect of haloperidol and ciproxifan on striatal proenkephalin mRNA expression

HAL moderately but significantly increased proenkephalin mRNA expression in the striatum as compared with saline administration (controls) (Fig. 2). In the caudate–putamen, a significant HAL-induced upregulation (by 30–40%) was found at 1, 2, and 20 mg/kg. In the nucleus accumbens, the increase in PE mRNA expression induced by HAL occurred to a similar extent (+40%; *p* < 0.001) at 1 mg/kg but did not reach statistical significance at 2 and 20 mg/kg (Table 1, Fig. 2). The administration of ciproxifan, an H<sub>3</sub>R antagonist/inverse agonist (1.5 mg/kg, i.p.), did not modify by itself PE mRNA expression in the caudate–putamen and nucleus accumbens (99 ± 8% and 102 ± 8% of controls, respectively) (Fig. 2), but potentiated HAL-induced upregulation in both regions. Both in the caudate–putamen and nucleus accumbens, ciproxifan significantly potentiated (by 60–70%) the upregulation evoked by 1 mg/kg of haloperidol (Fig. 2, Table 1), an effect that was completely blocked after coadministration of (*R*)-α-methylhistamine, an H<sub>3</sub>R agonist (10 mg/kg, i.p.)




**Figure 1.** Colocalization of H<sub>3</sub>R and PE mRNAs in rat striatum. *A, B*, Autoradiographic distribution of H<sub>3</sub>R (*A*) and PE (*B*) gene transcripts in frontal sections of the rat brain (interaural distance: 10.2 mm), visualized using <sup>33</sup>P-labeled antisense riboprobes. *C–F*, Sections of the caudate-putamen were hybridized with a H<sub>3</sub>R <sup>33</sup>P-labeled- and a PE digoxigenin-labeled antisense riboprobe. The cellular localization of PE mRNAs was revealed in a first step using an anti-digoxigenin antibody, and the colocalization of H<sub>3</sub>R mRNAs with the latter was revealed in a second step using a photographic emulsion (bright-field photomicrographs). Among neurons expressing PE mRNAs (in dark), ~70% coexpressed H<sub>3</sub>R mRNAs (*C*) (neurons expressing PE mRNAs alone or together with H<sub>3</sub>R mRNAs are shown at a higher magnification in *D* and *F*, respectively). Note that many striatal neurons did not express PE mRNAs but expressed H<sub>3</sub>R mRNAs (as revealed by dark autoradiographic grains in *C* and *E*).

(Fig. 2). The ciproxifan-evoked potentiation observed in both regions was not observed or did not reach statistical significance when the same dose of ciproxifan was coadministered with 2 or 20 mg/kg of haloperidol (Table 1).

#### Effect of haloperidol and ciproxifan on striatal proneurotensin mRNA expression

The level of proneurotensin mRNA expression observed in the striatum after intraperitoneal administration of saline (control) was very low (Fig. 3). It was dramatically increased in the caudate-putamen and nucleus accumbens 3 hr after intraperitoneal administration of haloperidol. HAL-evoked upregulation was much higher in the caudate-putamen (particularly in its dorso-lateral part) than in the nucleus accumbens with 100-fold and sevenfold increases, respectively. In both regions, the effect of haloperidol was dose-dependent with a subthreshold increase observed at 1 mg/kg and the maximal change reached at 2 mg/kg and 20 mg/kg (Table 2, Fig. 3). Ciproxifan used alone (1.5 mg/kg, i.p.), did not modify striatal proneurotensin mRNA expression, which represented  $102 \pm 5\%$  and  $86 \pm 14\%$  in the caudate-putamen and nucleus accumbens, respectively, but potentiated HAL-induced upregulation (Fig. 3). In both regions, ciproxifan potentiated by 70% the upregulation evoked by 1 mg/kg of haloperidol (Fig. 3, Table 2). This effect was reduced by 80% in the caudate-putamen and was completely blocked in the nucleus accumbens, after coadministration of (*R*)- $\alpha$ -methylhistamine (10 mg/kg, i.p.) (Fig. 3). The potentiation evoked by ciproxifan was strongly dependent on the dose of haloperidol and was no more



**Figure 2.** Potentiation by ciproxifan of the upregulation of proenkephalin mRNA expression elicited by haloperidol in the rat striatum. *Top*, The proenkephalin mRNAs were visualized by *in situ* hybridization on films 3 hr after intraperitoneal administration of saline solution (*CONTROL*), haloperidol (*HAL*, 1 mg/kg) alone or together with ciproxifan (*CPX*, 1.5 mg/kg), and, when required, (*R*)- $\alpha$ -methylhistamine [*(R)*-MeHA, 10 mg/kg]. *Bottom*, Quantification of mRNA signals observed in the caudate-putamen and nucleus accumbens. Results are means  $\pm$  SEM of values from 5–10 animals, expressed as percentage of proenkephalin mRNA level in control rats. \*\*\**p* < 0.001 versus control; £*p* < 0.05, ££*p* < 0.01 versus HAL; #*p* < 0.05, ##*p* < 0.01 versus HAL + CPX.



**Table 1. Effect of ciproxifan on the upregulation of proenkephalin mRNA expression elicited by administration of haloperidol in increasing dosages**

Treatment	Proenkephalin mRNA (% of control)	
	Caudate–putamen	Nucleus accumbens
Control	100 ± 6	100 ± 6
HAL 1 mg/kg	134 ± 5***	140 ± 8***
HAL 1 mg/kg + CPX	154 ± 7***,£	169 ± 6***,££
HAL 2 mg/kg	141 ± 18*	125 ± 19
HAL 2 mg/kg + CPX	171 ± 20***	162 ± 37
HAL 20 mg/kg	142 ± 12*	187 ± 59
HAL 20 mg/kg + CPX	164 ± 10**	172 ± 32

The proenkephalin mRNAs visualized on films 3 hr after intraperitoneal administration of saline (control), haloperidol (HAL, 1, 2, or 20 mg/kg) alone or in combination with ciproxifan (CPX, 1.5 mg/kg), were quantified in the caudate–putamen and nucleus accumbens. Results are means ± SEM of values from 4–10 animals, expressed as percentage of proenkephalin mRNA level in control rats. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  versus control; £ $p < 0.05$ , ££ $p < 0.01$  versus HAL.

observed when ciproxifan was coadministered with 2 or 20 mg/kg of haloperidol (Table 2).



#### Effect of haloperidol and ciproxifan on striatal c-fos mRNA expression

A threefold to fourfold increase of c-fos mRNA expression was found in the caudate–putamen and nucleus accumbens 1 hr after administration of haloperidol (1 mg/kg, i.p.) (Fig. 4). Ciproxifan (1.5 mg/kg, i.p.) did not change by itself c-fos mRNA expression (data not shown), but significantly potentiated (by 60 and 80%, respectively) the upregulation induced by haloperidol in both regions (Fig. 4).

#### Effect of haloperidol and ciproxifan on spontaneous locomotor activity and catalepsy

Spontaneous locomotor activity of rats was measured for 60 min after intraperitoneal administration of the drugs, and two-way ANOVA indicated that it decreased with time ( $F_{(5,450)} = 106.65$ ;  $p < 0.0001$ ) (Fig. 5A). A low dose of haloperidol (0.1 mg/kg, i.p.) induced a significant hypolocomotor effect, as compared with saline (controls) ( $F_{(1,66)} = 10.93$ ;  $p = 0.001$ ) (Fig. 5A). The cumulative measurement for 60 min showed that haloperidol decreased the overall spontaneous activity by 30% (Fig. 5B). Neither ciproxifan (1.5 mg/kg, i.p.) nor (R)- $\alpha$ -methylhistamine (10 mg/kg, i.p.) did modify spontaneous locomotor activity, as indicated by the cumulative values for 60 min, which represented  $112 \pm 11\%$  and  $100 \pm 11\%$  of controls, respectively (Fig. 5B). However, ciproxifan used at the same dose significantly potentiated (by 70%) the hypolocomotor effect of haloperidol ( $F_{(1,59)} = 9.56$ ;  $p = 0.003$ ). *Post hoc* analysis revealed a significant potentiation by ciproxifan after 10 min ( $p < 0.001$ ) and at set times 20, 40, and 50 min, the hypolocomotion induced by the coadministration of haloperidol and ciproxifan reached a higher degree of significance compared with controls than that induced by haloperidol alone (Fig. 5A). In addition, the cumulative locomotor activity for 60 min represented  $66 \pm 5\%$  and  $42 \pm 4\%$  of controls after administration of haloperidol alone or in combination with ciproxifan, respectively, leading to a 70% potentiation by ciproxifan ( $p < 0.01$ ) (Fig. 5B). This potentiating effect was completely blocked by the coadministration of (R)- $\alpha$ -methylhistamine because the spontaneous locomotor activity then represented  $77 \pm 12\%$  of controls (Fig. 5B).

The same low dose of haloperidol (0.1 mg/kg) induced cata-



**Figure 3.** Potentiation by ciproxifan of the upregulation of proneurotensin mRNA expression elicited by haloperidol in the rat striatum. *Top*, The proneurotensin mRNAs were visualized by *in situ* hybridization on films 3 hr after intraperitoneal administration of saline solution (CONTROL), haloperidol (HAL, 1 mg/kg) alone or together with ciproxifan (CPX, 1.5 mg/kg), and, when required, (R)- $\alpha$ -methylhistamine [(R)- $\alpha$ -MeHA, 10 mg/kg]. *Bottom*, Quantification of mRNA signals observed in the caudate–putamen and nucleus accumbens. Results are means ± SEM of values from 4–10 animals, expressed as percentage of proneurotensin mRNA level in control rats. \* $p < 0.05$ , \*\* $p < 0.001$  versus control; £ $p < 0.05$ , ££ $p < 0.01$  versus HAL; # $p < 0.05$ , ## $p < 0.01$  versus HAL + CPX.

**Table 2. Effect of ciproxifan on the upregulation of proneurotensin mRNA expression elicited by administration of haloperidol in increasing dosages**

Treatment	Proneurotensin mRNA (% of control)	
	Caudate–putamen	Nucleus accumbens
Control	100 ± 6	100 ± 11
HAL 1 mg/kg	409 ± 70**	148 ± 11*
HAL 1 mg/kg + CPX	632 ± 38** <sup>££</sup>	179 ± 13** <sup>£</sup>
HAL 2 mg/kg	13127 ± 1759**	697 ± 92**
HAL 2 mg/kg + CPX	9790 ± 1319**	524 ± 34**
HAL 20 mg/kg	10710 ± 2335**	696 ± 135**
HAL 20 mg/kg + CPX	8774 ± 1324**	599 ± 105**


The proneurotensin mRNA hybridization signals were quantified 3 hr after intraperitoneal administration of saline (control) or drugs. Results are means ± SEM of values from 4–10 animals, expressed as percentage of proneurotensin mRNA level in control rats. \* $p < 0.05$ ; \*\* $p < 0.001$  versus control; <sup>£</sup> $p < 0.05$ , <sup>££</sup> $p < 0.01$  versus HAL.

lepsy in 2 of 12 rats. Whereas no catalepsy was observed during 2 hr after intraperitoneal administration of ciproxifan alone (1.5 mg/kg), the coadministration of ciproxifan (1.5 mg/kg) with haloperidol (0.1 mg/kg) induced catalepsy in all the animals tested, i.e., in 12 of 12 rats. The number of cataleptic animals was reduced to three of eight when (*R*)- $\alpha$ -methylhistamine (10 mg/kg, i.p.) was administered together with the two compounds (Table 3).

## DISCUSSION

The first finding of this study is that striatal enkephalin neurons express H<sub>3</sub>Rs. H<sub>3</sub>Rs were already shown on striatonigral neurons of the direct pathway (Ryu et al., 1994a, 1996; Garcia et al., 1997; Arias-Montano et al., 2001). The coexpression of H<sub>3</sub>R and proenkephalin mRNAs that we evidence here shows that they are also present on projection neurons of the indirect pathway. Enkephalin expression is selectively found in striatopallidal neurons (Reiner and Anderson, 1990; Gerfen, 1992) and parallels their activity (Gerfen et al., 1990; Angulo and McEwen, 1994), which may account for the variable density of proenkephalin mRNAs that we observed within neurons positively labeled by *in situ* hybridization. H<sub>3</sub>R mRNA expression itself may be dependent on enkephalin neuron activity because it was not observed in all these neurons and was increased in the external pallidum of patients with Parkinson's disease (Anichtchik et al., 2001). H<sub>3</sub>R mRNAs within enkephalin neurons probably account for the dense H<sub>3</sub>R binding in the external pallidum in rat (Pillot et al., 2002) and human (Martinez-Mir et al., 1990), inasmuch as the latter is dramatically reduced in Huntington's disease (Goodchild et al., 1999), which is characterized by degeneration of projection neurons (Albin et al., 1989).


The coexpression of proenkephalin and H<sub>3</sub>R mRNAs prompted us to explore the effect of H<sub>3</sub>R ligands on striatal enkephalin expression. Enkephalin expression is known to be inhibited by D<sub>2</sub> receptors, leading to its increase by haloperidol in the caudate–putamen and nucleus accumbens, two structures with similar organizations (Heimer et al., 1985; Svensson et al., 1995). Although upregulation of proenkephalin mRNAs was mainly reported after chronic treatments (Tang et al., 1983; Romano et al., 1987; Morris et al., 1988; Angulo et al., 1990), our data confirm that it is also observed after acute administration of haloperidol (Angulo, 1992). As expected (Deutch et al., 1992; Merchant and Dorsa, 1993), the same treatment also upregulated



**Figure 4.** Potentiation by ciproxifan of the upregulation of c-fos mRNA expression elicited by haloperidol in the rat striatum. c-fos hybridization signals were quantified on films 1 hr after intraperitoneal administration of saline solution (CONTROL), haloperidol (HAL, 1 mg/kg) alone or together with ciproxifan (CPX, 1.5 mg/kg). Results are means ± SEM of values from 7–10 animals, expressed as percentage of c-fos mRNA level in control rats. \* $p < 0.05$ , \*\* $p < 0.001$  versus control; <sup>£</sup> $p < 0.05$  versus HAL.

proneurotensin mRNAs. It remains unclear whether neurotensin and enkephalin were upregulated within the same cells. Neurotensin striatopallidal neurons have been described (Sugimoto and Mizuno, 1987; Fuxe et al., 1992), and neurotensin cells regulated by D<sub>2</sub> receptors may represent striatopallidal neurons (Castel et al., 1994). However, as already described (Angulo, 1992; Merchant et al., 1992), we observed that enkephalin was moderately and homogeneously upregulated within the striatum, whereas the neurotensin upregulation was much higher in the caudate–putamen, particularly in its dorsolateral part, than in the nucleus accumbens. Moreover, the two systems responded differently to haloperidol because the dose of 1 mg/kg induced subthreshold neurotensin and submaximal enkephalin upregulations, respectively.

An important finding is that ciproxifan, a H<sub>3</sub>R antagonist/inverse agonist (Ligneau et al., 1998; Morisset et al., 2000), strongly potentiates the upregulation of proenkephalin and proneurotensin mRNAs elicited by haloperidol. This potentiation



**Figure 5.** Potentiation by ciproxifan of the decrease in spontaneous locomotor activity elicited by haloperidol in the rat. The spontaneous locomotor activity of 8–36 animals was evaluated after intraperitoneal administration of saline solution (*CONTROL*), haloperidol (*HAL*, 0.1 mg/kg), ciproxifan (*CPX*, 1.5 mg/kg), or (*R*)- $\alpha$ -methylhistamine [(*R*)-*MeHA*, 10 mg/kg], alone or in combination. *A*, Each point represents the cumulative photocell counts measured for each 10 min interval during 1 hr. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  versus control;  $\xi p < 0.001$  versus HAL in two-way ANOVA followed by LSD *post hoc* tests. *B*, The cumulative photocell counts were measured for 60 min after administration of the compounds. Results are means  $\pm$  SEM expressed as percentage of the value obtained for control rats. \* $p < 0.001$  versus control;  $\xi p < 0.01$  versus HAL; # $p < 0.05$  versus HAL+CPX in one-way ANOVA followed by Newman–Keuls test.

occurred in the caudate–putamen and nucleus accumbens and was H<sub>3</sub>R-mediated, being suppressed by (*R*)- $\alpha$ -methylhistamine, a prototypical H<sub>3</sub>R agonist (Arrang et al., 1987). However, the mechanisms involved remain unclear. H<sub>3</sub>R<sub>s</sub> modulate striatal dopamine and glutamate release (Schlicker et al., 1994; Molina-Hernandez et al., 2001) but their *in vivo* contribution remains doubtful (Blandina et al., 1998). Similarly, it remains unclear if D<sub>1</sub>-receptors upregulating enkephalin are activated by endogenous dopamine under basal conditions (Wang and McGinty, 1997; Alburges et al., 2001). The absence of modulation by ciproxifan used alone and *in situ* hybridization data rather suggest that the effect of ciproxifan results from synergistic interactions between H<sub>3</sub> and D<sub>2</sub> receptors located within the same striatal neurons. Most enkephalin neurons express H<sub>3</sub> and D<sub>2</sub> receptors

**Table 3.** Effect of ciproxifan on haloperidol-induced catalepsy in the rat

Drugs	Catalepsy
HAL (0.1 mg/kg)	2/12
CPX (1.5 mg/kg)	0/8
HAL + CPX	12/12
HAL + CPX + ( <i>R</i> )- $\alpha$ -MeHA (10 mg/kg)	3/8

Catalepsy was assessed in an all-or-none manner 2 hr after intraperitoneal administration of the drugs. The number of animals in catalepsy out of the total number of animals (8–12) is indicated.

(Le Moine and Bloch, 1995), indicating that both receptors are coexpressed in striatopallidal neurons. Therefore, the potentiation of haloperidol by ciproxifan may result from direct synergistic interactions between H<sub>3</sub> and D<sub>2</sub> receptors via their transduction pathway or pathways, inasmuch as both receptors couple to G<sub>i</sub>/G<sub>o</sub>-proteins in the brain (Vallar and Meldolesi, 1989; Clark and Hill, 1996; Takeshita et al., 1998). Consistent with such synergistic interactions, ciproxifan potentiated a subthreshold dose of haloperidol (1 mg/kg) but not maximally effective doses (2–20 mg/kg) on neurotensin upregulation.

Previous studies suggested that proenkephalin and neurotensin genes were physiological targets for Fos (Sonnenberg et al., 1990; Merchant and Dorsa, 1993; Merchant, 1994). Haloperidol upregulates Fos expression in the caudate–putamen and nucleus accumbens (Dragunow et al., 1990; Deutch et al., 1992; Nguyen et al., 1992; Merchant and Miller, 1994) and predominantly within striatopallidal neurons (Robertson et al., 1992). Interestingly, ciproxifan potentiated the haloperidol-induced upregulation of c-fos mRNAs, but had no effect when used alone, suggesting the involvement of Fos in the potentiation of neuropeptide expression.

The effect of ciproxifan on c-fos, a marker of neuronal activation (Morgan and Curran, 1991), further suggests that H<sub>3</sub>R antagonists/inverse agonists potentiate the activation of striatopallidal neurons induced by neuroleptics. The synergistic motor effects of ciproxifan and haloperidol are also consistent with this proposal. Blockade of D<sub>2</sub> receptors, by activating striatopallidal neurons of the indirect pathway, leads to inhibition of motor functions, e.g., catalepsy and locomotor hypoactivity. Therefore, the enhanced activation of striatopallidal neurons by ciproxifan was expected to potentiate haloperidol-induced motor effects. Indeed, ciproxifan dramatically potentiated haloperidol-induced catalepsy. This effect was suppressed by (*R*)- $\alpha$ -methylhistamine, confirming the involvement of H<sub>3</sub>R<sub>s</sub>. Although a functional distinction between the dorsal striatum and nucleus accumbens is not entirely well founded (Carlsson, 1993; Carlsson et al., 1997) and additional structures might contribute to catalepsy (Hauber, 1998), the crucial role of the dorsal striatum in voluntary movements (Albin et al., 1995) suggests that the potentiation of catalepsy results from H<sub>3</sub>/D<sub>2</sub>-receptor interactions in this structure. Recently (Morisset et al., 1999), we failed to detect in mice the potentiation of haloperidol-induced catalepsy that we evidence here in rats. However, besides species differences, we used a higher dose of haloperidol in mice. This may suggest that the potentiation of catalepsy is also dependent on the dose of haloperidol and supports synergistic interactions between D<sub>2</sub> and H<sub>3</sub> receptors. The absence of catalepsy after administration of ciproxifan alone in mice (Morisset et al., 1999) or rats suggests that H<sub>3</sub>R<sub>s</sub> are not involved in this behavior under basal conditions. Interestingly, H<sub>3</sub>R<sub>s</sub> do not regulate dopamine neuron activity *in*



*vivo* (Oishi et al., 1990; Imaizumi and Onodera, 1993; Miyazaki et al., 1997). H<sub>3</sub>R antagonists/inverse agonists are proposed to improve cognitive deficits (Ligneau et al., 1998; Bacciottini et al., 2001). Our data predict that no extrapyramidal side effects should result from their therapeutic use.

As also expected from an enhanced activation of striatopallidal neurons, ciproxifan potentiated haloperidol-induced locomotor hypoactivity. This effect may result from an enhanced activation of neurons from the nucleus accumbens, known to play a crucial role in the regulation of locomotor function (Svensson et al., 1995). Like thioperamide (Imaizumi and Onodera, 1993; Clapham and Kilpatrick, 1994), ciproxifan did not change spontaneous locomotor activity when used alone. We also confirmed that activation of H<sub>3</sub>Rs by (*R*)- $\alpha$ -methylhistamine had no effect (Clapham and Kilpatrick, 1994). These data on catalepsy and locomotor activity suggest that H<sub>3</sub>Rs do not play an important role in motor functions under basal conditions, a proposal consistent with our neurochemical findings.

The potentiation of haloperidol by ciproxifan suggests that endogenous histamine and dopamine cooperate to modulate the activity of the indirect pathway. However, native H<sub>3</sub>Rs in brain display high constitutive activity that is abrogated by ciproxifan acting as an inverse agonist (Morisset et al., 2000; Rouleau et al., 2002). H<sub>3</sub>Rs mediating the present effects may therefore be spontaneously active in the absence of histamine. No other data are available on the effect of endogenous histamine on neuropeptide expression and catalepsy. Central administration of histamine modulated spontaneous locomotor activity (Nistico et al., 1980; Tuomisto and Eriksson, 1980; Kalivas, 1982; Bristow and Bennett, 1988; Chiavegatto et al., 1998). However, the role of endogenous histamine remained unclear (Sakai et al., 1992; Inoue et al., 1996; Yanai et al., 1998), and our data do not support such a role under basal conditions because ciproxifan, which potently enhances histamine release *in vivo* (Ligneau et al., 1998; Morisset et al., 2000), did not modify locomotor activity when used alone.

The locomotor hypoactivity induced by ciproxifan was revealed when the dopaminergic transmission was reduced by haloperidol. Interestingly, ciproxifan and thioperamide also decreased locomotion induced by dopaminergic agonists (Clapham and Kilpatrick, 1994; Morisset et al., 2002). Whether these hypoactivities result from the same mechanisms remains unknown. The involvement of H<sub>3</sub>Rs coexpressed with D<sub>2</sub> receptors in striatopallidal neurons would suggest that histamine cooperates with dopamine to induce motor hyperactivity. However, previous studies suggested that endogenous histamine inhibits motor hyperactivity induced by methamphetamine (Itoh et al., 1984; Clapham and Kilpatrick, 1994; Ito et al., 1997; Morisset et al., 2002).

In summary, the H<sub>3</sub>R mRNA expression in enkephalin neurons and the synergistic neurochemical and motor effects of ciproxifan and haloperidol support the existence of direct functional H<sub>3</sub>/D<sub>2</sub>-receptor interactions in striatopallidal neurons of the indirect pathway. In addition to their procognitive properties against the negative symptomatology of the disease (Morisset et al., 1999), the potentiation of the effects of haloperidol by ciproxifan suggests that H<sub>3</sub>R antagonists/inverse agonists might be helpful to improve the symptomatic treatment of schizophrenia.

## REFERENCES

Albin RL, Young AB, Penney JB (1989) The functional neuroanatomy of basal ganglia disorders. *Trends Neurosci* 12:366–375.  
 Albin RL, Young AB, Penney JB (1995) The functional anatomy of disorders of the basal ganglia. *Trends Neurosci* 18:63–64.  
 Alburges ME, Keefe KA, Hanson GR (2001) Contrasting responses by

basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model. *J Neurochem* 76:721–729.  
 Angulo JA (1992) Involvement of dopamine D<sub>1</sub> and D<sub>2</sub> receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. *J Neurochem* 58:1104–1109.  
 Angulo JA, McEwen BS (1994) Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. *Brain Res Rev* 19:1–28.  
 Angulo JA, Cadet JL, Woolley CS, Suber F, McEwen BS (1990) Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat. *J Neurochem* 54:1889–1894.  
 Anichtchik OV, Huotari M, Peitsaro N, Haycock JW, Mannisto PT, Panula P (2000) Modulation of histamine H<sub>3</sub> receptors in the brain of 6-hydroxydopamine-lesioned rats. *Eur J Neurosci* 12:3823–3832.  
 Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H, Panula P (2001) Distribution and modulation of histamine H<sub>3</sub> receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. *Neurobiol Dis* 8:707–716.  
 Arias-Montano JA, Floran B, Garcia M, Aceves J, Young JM (2001) Histamine H<sub>3</sub> receptor-mediated inhibition of depolarization-induced, dopamine D<sub>1</sub> receptor-dependent release of [<sup>3</sup>H]- $\gamma$ -aminobutyric acid from rat striatal slices. *Br J Pharmacol* 133:165–171.  
 Arrang JM, Garbarg M, Schwartz JC (1983) Autoinhibition of histamine release mediated by a novel class (H<sub>3</sub>) of histamine receptor. *Nature* 302:832–837.  
 Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC (1987) Highly potent and selective ligands for histamine H<sub>3</sub>-receptors. *Nature* 327:117–123.  
 Bacciottini L, Passani MB, Mannaioni PF, Blandina P (2001) Interactions between histaminergic and cholinergic systems in learning and memory. *Behav Brain Res* 124:183–194.  
 Barbin G, Palacios JM, Rodergas E, Schwartz JC, Garbarg M (1980) Characterization of the high-affinity binding sites of [<sup>3</sup>H]histamine in rat brain. *Mol Pharmacol* 18:1–10.  
 Blandina P, Bacciottini L, Giovannini MG, Mannaioni PF (1998) H<sub>3</sub> receptor modulation of the release of neurotransmitters *in vivo*. In: *The Histamine H<sub>3</sub> Receptor* (Leurs R, Timmermann H, eds), pp 27–40. Amsterdam: Elsevier.  
 Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. *Eur J Neurosci* 12:2117–2123.  
 Brown RE, Stevens DR, Haas HL (2001) The physiology of brain histamine. *Prog Neurobiol* 63:637–672.  
 Bristow LJ, Bennett GW (1988) Biphasic effects of intra-accumbens histamine administration on spontaneous motor activity in the rat: a role for central histamine receptors. *Br J Pharmacol* 95:1292–1302.  
 Carlsson A (1993) On the neuronal circuitries and neurotransmitters involved in the control of locomotor activity. *J Neural Trans* 40:1–12.  
 Carlsson A, Hansson LO, Waters N, Carlsson ML (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. *Life Sci* 61:75–94.  
 Castel MN, Morino P, Dagerlind A, Hökfelt (1994) Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment. *Eur J Neurosci* 6:646–656.  
 Chiavegatto S, Nasello AG, Bernardi MM (1998) Histamine and spontaneous motor activity: biphasic changes, receptors involved and participation of the striatal dopamine system. *Life Sci* 62:1875–1888.  
 Clapham J, Kilpatrick GJ (1994) Thioperamide, the selective histamine H<sub>3</sub> receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. *Eur J Pharmacol* 259:107–114.  
 Clark EA, Hill SJ (1996) Sensitivity of histamine H<sub>3</sub> receptor agonist-stimulated [<sup>35</sup>S]GTP $\gamma$ [S] binding to pertussis toxin. *Eur J Pharmacol* 296:223–225.  
 Cumming P, Shaw C, Vincent SR (1991) High affinity histamine binding is the H<sub>3</sub> receptor: characterization and autoradiographic localization in rat brain. *Synapse* 8:144–151.  
 Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. *Mol Cell Neurosci* 3:332–341.  
 Dragnow M, Robertson GS, Fuall RLM, Robertson HA, Jansen K (1990) D<sub>2</sub> dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. *Neuroscience* 37:287–294.  
 Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H, Panula P, Leurs R (2001) Identification of rat H<sub>3</sub> receptor isoforms with different brain expression and signaling properties. *Mol Pharmacol* 59:1–8.  
 Fuxe K, von Euler G, Agnati LF, Merlo Pich E, O'Connor WT, Tanganelli S, Li XM, Tinner B, Cintra A, Carani C, Benfenati F (1992) Intramembrane interactions between neurotensin receptors and dopamine D<sub>2</sub> receptors as a major mechanism for the neuroleptic-like action of neurotensin. *Ann NY Acad Sci* 668:186–204.  
 Garcia M, Floran B, Arias-Montano JA, Young JM, Aceves J (1997) Histamine H<sub>3</sub> receptor activation selectively inhibits dopamine D<sub>1</sub>



- receptor-dependent [ $^3\text{H}$ ]- $\gamma$ -aminobutyric acid release from depolarisation-stimulated slices of rat substantia nigra pars reticulata. *Neuroscience* 80:241–249.
- Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. *Annu Rev Neurosci* 15:285–320.
- Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR (1990) D<sub>1</sub> and D<sub>2</sub> dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. *Science* 250:1429–1432.
- Goodchild RE, Court JA, Hobson I, Piggott MA, Perry RH, Ince P, Jaros E, Perry EK (1999) Distribution of histamine H<sub>3</sub>-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. *Eur J Neurosci* 11:449–456.
- Haubert W (1998) Involvement of basal ganglia transmitter systems in movement initiation. *Prog Neurobiol* 56:507–540.
- Heimer L, Alheid GF, Zaborsky L (1985) Basal ganglia. In: *The rat nervous system*, Vol 1, Forebrain and midbrain (Paxinos G, ed), pp 37–86. New York: Academic.
- Héron A, Rouleau A, Cochois V, Pillot C, Schwartz JC, Arrang JM (2001) Expression analysis of the histamine H<sub>3</sub> receptor in developing rat tissues. *Mech Dev* 105:167–173.
- Imaizumi M, Onodera K (1993) The behavioral and biochemical effects of thioperamide, a histamine H<sub>3</sub>-receptor antagonist, in a light dark test measuring anxiety in mice. *Life Sci* 53:1675–1683.
- Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H<sub>1</sub> receptors. *Proc Natl Acad Sci USA* 93:13316–13320.
- Ito C, Onodera K, Sakurai E, Sato M, Watanabe T (1996) Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. *J Pharmacol Exp Ther* 279:271–276.
- Ito C, Onodera K, Watanabe T, Sato M (1997) Effects of histamine agents on methamphetamine-induced stereotyped behavior and behavioral sensitization in rats. *Psychopharmacology* 130:362–367.
- Itoh Y, Nishibori M, Oishi R, Saeki K (1984) Neuronal histamine inhibits methamphetamine-induced locomotor hyperactivity in mice. *Neurosci Lett* 48:305–309.
- Kalivas PW (1982) Histamine induced arousal in the conscious and pentobarbital rat. *J Pharmacol Exp Ther* 222:37–42.
- Le Moine C, Bloch B (1995) D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. *J Comp Neurol* 355:418–426.
- Ligneau X, Lin JS, Vanni-Mercier G, Jouvét M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz JC (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H<sub>3</sub>-receptor antagonist. *J Pharmacol Exp Ther* 287:658–666.
- Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, Erlander MG (1999) Cloning and functional expression of the human histamine H<sub>3</sub> receptor. *Mol Pharmacol* 55:1101–1107.
- Lovenberg TW, Pyati J, Chang H, Wilson SJ, Erlander MG (2000) Cloning of rat histamine H<sub>3</sub> receptor reveals distinct species pharmacological profiles. *J Pharmacol Exp Ther* 293:771–778.
- Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM (1990) Three histamine receptors (H<sub>1</sub>, H<sub>2</sub> and H<sub>3</sub>) visualized in the brain of human and non-human primates. *Brain Res* 526:322–327.
- Merchant KM (1994) *c-fos* Antisense oligonucleotide specifically attenuates haloperidol-induced increases in the neurotensin-neuromedin N mRNA expression in the dorsal striatum. *Mol Cell Neurosci* 5:336–344.
- Merchant KM, Dorsa DM (1993) Differential induction of neurotensin and *c-fos* gene expression by typical versus atypical antipsychotics. *Proc Natl Acad Sci USA* 90:3447–3451.
- Merchant KM, Miller MA (1994) Coexpression of neurotensin and *c-fos* mRNAs in rat neostriatal neurons following acute haloperidol. *Mol Brain Res* 23:271–277.
- Merchant KM, Dobner PR, Dorsa DM (1992) Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. *J Neurosci* 12:652–663.
- Miyazaki S, Onodera K, Imaizumi M, Timmerman H (1997) Effects of clobenpropit (VUF-9153), a histamine H<sub>3</sub>-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in mice. *Life Sci* 61:355–361.
- Molina-Hernandez A, Nunez A, Sierra JJ, Arias-Montano JA (2001) Histamine H<sub>3</sub> receptor activation inhibits glutamate release from rat striatal synaptosomes. *Neuropharmacology* 41:928–934.
- Morgan JJ, Curran T (1991) Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes *fos* and *jun*. *Annu Rev Neurosci* 14:421–451.
- Morisset S, Sahn UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC (1999) Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine<sub>2A</sub> receptor blockade. *J Pharmacol Exp Ther* 288:590–596.
- Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM (2000) High constitutive activity of native H<sub>3</sub> receptors regulates histamine neurons in brain. *Nature* 408:860–864.
- Morisset S, Sasse A, Gbahou F, Héron A, Ligneau X, Tardivel-Lacombe J, Schwartz JC, Arrang JM (2001) The rat H<sub>3</sub> receptor: gene organization and multiple isoforms. *Biochem Biophys Res Commun* 280:75–80.
- Morisset S, Pilon C, Tardivel-Lacombe J, Weinstein D, Rostene W, Betancur C, Sokoloff P, Schwartz JC, Arrang JM (2002) Acute and chronic effects of methamphetamine on *tele*-methylhistamine levels in mouse brain: selective involvement of the D<sub>2</sub> and not D<sub>3</sub> receptor. *J Pharmacol Exp Ther* 300:621–628.
- Morris B, Holt V, Herz A (1988) Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D<sub>1</sub> and D<sub>2</sub> antagonists. *Neuroscience* 25:525–532.
- Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE (1992) Differential expression of *c-fos* and *zif268* in rat striatum after haloperidol, clozapine, and amphetamine. *Proc Natl Acad Sci USA* 89:4270–4274.
- Nistico G, Rotiroli D, De Sarro A, Naccari F, Stephenson JD (1980) Central effects of histamine and H1 and H2 receptor agonists and antagonists after intraventricular infusion in fowls. *Res Commun Chem Pathol Pharmacol* 27:431–450.
- Oishi R, Nishibori M, Itoh Y, Shishido S, Saeki K (1990) Is monoamine turnover in the brain regulated by histamine H<sub>3</sub> receptors? *Eur J Pharmacol* 184:135–142.
- Onodera K, Yamatodani A, Watanabe T, Wada H (1994) Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. *Prog Neurobiol* 42:685–702.
- Parent A, Harati LN (1995) Functional anatomy of the basal ganglia. I. The cortical-basal ganglia-thalamo-cortical loop. *Brain Res Rev* 20:91–127.
- Pillot C, Héron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, Arrang JM (2002) A detailed mapping of the histamine H<sub>3</sub> receptor and its gene transcripts in rat brain. *Neuroscience*, in press.
- Pollard H, Moreau J, Arrang JM, Schwartz JC (1993) A detailed autoradiographic mapping of histamine H<sub>3</sub> receptors in rat brain areas. *Neuroscience* 52:169–189.
- Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. *Schizophr Res* 14:93–104.
- Reiner A, Anderson K (1990) The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings. *Brain Res Rev* 15:251–265.
- Robertson GS, Vincent SR, Fibiger HC (1992) D<sub>1</sub> and D<sub>2</sub> dopamine receptors differentially regulate *c-fos* expression in striatonigral and striatopallidal neurons. *Neuroscience* 49:285–296.
- Romano GJ, Shivers BD, Harlan RE, Howells RD, Pfaff DW (1987) Haloperidol increases proenkephalin mRNA levels in the caudate-putamen of the rat: a quantitative study at the cellular level using *in situ* hybridization. *Mol Brain Res* 2:33–41.
- Rouleau A, Ligneau X, Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz JC, Arrang JM (2002) Histamine H<sub>3</sub>-receptor-mediated [ $^{35}\text{S}$ ]GTP $\gamma$ [S] binding: evidence for constitutive activity of the recombinant and native rat and human H<sub>3</sub> receptors. *Br J Pharmacol* 135:383–392.
- Ryu JH, Yanai K, Iwata R, Ido T, Watanabe T (1994a) Heterogeneous distributions of histamine H<sub>3</sub>, dopamine D<sub>1</sub> and D<sub>2</sub> receptors in rat brain. *NeuroReport* 5:621–624.
- Ryu JH, Yanai K, Watanabe T (1994b) Marked increase in histamine H<sub>3</sub> receptors in the striatum and substantia nigra after 6-hydroxydopamine-induced denervation of dopaminergic neurons: an autoradiographic study. *Neurosci Lett* 178:19–22.
- Ryu JH, Yanai K, Sakurai E, Kim CY, Watanabe T (1995) Ontogenetic development of histamine receptor subtypes in rat brain demonstrated by quantitative autoradiography. *Dev Brain Res* 87:101–110.
- Ryu JH, Yanai K, Zhao XL, Watanabe T (1996) The effect of dopamine D<sub>1</sub> receptor stimulation on the up-regulation of histamine H<sub>3</sub>-receptors following destruction of the ascending dopaminergic neurons. *Br J Pharmacol* 118:585–592.
- Sakai N, Onodera K, Maeyama K, Yanai K, Watanabe T (1992) Effects of  $\alpha$ -fluoromethylhistidine and metoprine on locomotor activity and brain histamine contents in mice. *Life Sci* 51:397–405.
- Schlicker E, Malinowska B, Kathmann M, Göthert M (1994) Modulation of neurotransmitter release via histamine H<sub>3</sub> heteroreceptors. *Fund Clin Pharmacol* 8:128–137.
- Schwartz JC, Arrang JM (2002) Histamine. In: *Neuropsychopharmacology: the fifth generation of progress* (Davis KL, Charney D, Coyle JT, Nemeroff C, eds), pp 179–190. Philadelphia: Lippincott Williams and Wilkins.
- Sonnenberg JL, Rauscher FJ III, Morgan JJ, Curran T (1990) Regulation of proenkephalin by Fos and Jun. *Science* 246:1622–1625.

- Sugimoto T, Mizuno N (1987) Neurotensin in projection neurons of the striatum and nucleus accumbens, with reference to coexistence with enkephalin and GABA: an immunohistochemical study in the cat. *J Comp Neurol* 257:383–395.
- Svensson A, Carlsson ML, Carlsson A (1995) Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice. *J Neural Transm Gen Sect* 101: 127–148.
- Takeshita Y, Watanabe T, Sakata T, Munakata M, Ishibashi H, Akaike N (1998) Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus. *Neuroscience* 87:797–805.
- Tang F, Costa E, Schwartz JP (1983) Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. *Proc Natl Acad Sci USA* 80:3841–3844.
- Tardivel-Lacombe J, Rouleau A, Héron A, Morisset S, Pillot C, Cochois V, Schwartz JC, Arrang JM (2000) Cloning and cerebral expression of the guinea pig histamine H<sub>3</sub> receptor: evidence for two isoforms. *NeuroReport* 11:755–759.
- Tuomisto L, Eriksson L (1980) Cardiovascular and behavioural changes after i.c.v. infusions of histamine and agonists in conscious goat. *Agents Actions* 10:165–166.
- Vallar L, Meldolesi J (1989) Mechanisms of signal transduction at dopamine D<sub>2</sub> receptors. *Trends Pharmacol Sci* 10:74–77.
- Wang JQ, McGinty JF (1997) The full D<sub>1</sub> dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D<sub>1</sub>/D<sub>2</sub> interactions by muscarinic receptors. *J Pharmacol Exp Ther* 281:972–982.
- Yanai K, Son LZ, Endou M, Sakurai E, Nakagawasai O, Tadano T, Kisara K, Inoue I, Watanabe T, Watanabe T (1998) Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. *Neuroscience* 87:479–487.